MedTrace Logo

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 289

Last updated 2019-05-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.

Conditions

Interventions

DRUG

Cenicriviroc

CVC 150 mg, administered orally once daily and taken every morning with food.

DRUG

Placebo

Placebo administered orally once daily and taken every morning with food.

Sponsors & Collaborators

  • Tobira Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Lefebvre, MD · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-18
Primary Completion
2016-06-30
Completion
2017-06-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Germany
  • Hong Kong
  • Italy
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02217475 on ClinicalTrials.gov